TY - JOUR AU - Serumondo, Janvier AU - Penkunas, Michael J. AU - Niyikora, Julienne AU - Ngwije, Alida AU - Kiromera, Athanase AU - Musabeyezu, Emmanuel AU - Umutesi, Justine AU - Umuraza, Sabine AU - Musengimana, Gentille AU - Nsanzimana, Sabin PY - 2020 DA - 2020/06/16 TI - Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators JO - BMC Public Health SP - 946 VL - 20 IS - 1 AB - Direct-acting antivirals (DAAs) are increasingly accessible to patients with hepatitis C (HCV) worldwide and are being introduced through national health systems in sub-Saharan Africa. DAAs are highly efficacious when tested in controlled trials, yet patients treated outside of study settings often encounter challenges in completing the full treatment and follow-up sequence. Little information is available on the influences of successful DAA implementation in sub-Saharan Africa. This qualitative study explored the individual- and system-level barriers and enablers of DAA treatment in Rwanda between March 2015 and November 2017. SN - 1471-2458 UR - https://doi.org/10.1186/s12889-020-09000-0 DO - 10.1186/s12889-020-09000-0 ID - Serumondo2020 ER -